Tags

Type your tag names separated by a space and hit enter

[Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia].
Zhonghua Nan Ke Xue. 2005 Sep; 11(9):674-6.ZN

Abstract

OBJECTIVE

To study the efficacy and safety of Eviprostat for the treatment of benign prostatic hyperplasia (BPH).

METHODS

An open, multicentral clinical trial was conducted in 100 patients with BPH. Patients received a 12-week oral administration of Eviprostat 2 tablets per-time, 3 times a day. The main indexes of efficacy include international prostatic symptom score (IPSS), maximum urinary flow rate (Qmax), residual urine (Ru) and prostatic volume (V). The additional indexes are quality of life score (QOL) and average urinary flow rate (Qave).

RESULTS

After a 12-week therapy, IPSS, QOL score, Qmax and Qave were significantly improved. IPSS was averagely decreased by 5.67 (P < 0.001); QOL score was averagely decreased by 1.44 (P < 0.001); Qmax was averagely increased by 1.70 ml/s (P <0.001); Qave was averagely increased by 1.15 ml/s (P < 0.001); Ru was averagely decreased by 5.07 ml (P = 0.046) , PSA level was averagely decreased by 0.129 microg/L (P < 0.017). The clinical adverse event rate was 1%.

CONCLUSION

Eviprostat is a kind of safe, effective and preferable drug for treating BPH. It can improve the subjective symptoms and objective measures of the patients.

Authors+Show Affiliations

Institute of Urology, the First Hospital of Peking University, Beijing 100034, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Multicenter Study

Language

chi

PubMed ID

16209208

Citation

Song, Yi, et al. "[Clinical Study of Eviprostat for the Treatment of Benign Prostatic Hyperplasia]." Zhonghua Nan Ke Xue = National Journal of Andrology, vol. 11, no. 9, 2005, pp. 674-6.
Song Y, Li NC, Wang XF, et al. [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia]. Zhonghua Nan Ke Xue. 2005;11(9):674-6.
Song, Y., Li, N. C., Wang, X. F., Ma, L. L., Wan, B., Hong, B. F., & Na, Y. Q. (2005). [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia]. Zhonghua Nan Ke Xue = National Journal of Andrology, 11(9), 674-6.
Song Y, et al. [Clinical Study of Eviprostat for the Treatment of Benign Prostatic Hyperplasia]. Zhonghua Nan Ke Xue. 2005;11(9):674-6. PubMed PMID: 16209208.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia]. AU - Song,Yi, AU - Li,Ning-chen, AU - Wang,Xiao-feng, AU - Ma,Lu-lin, AU - Wan,Ben, AU - Hong,Bao-fa, AU - Na,Yan-qun, PY - 2005/10/8/pubmed PY - 2007/4/25/medline PY - 2005/10/8/entrez SP - 674 EP - 6 JF - Zhonghua nan ke xue = National journal of andrology JO - Zhonghua Nan Ke Xue VL - 11 IS - 9 N2 - OBJECTIVE: To study the efficacy and safety of Eviprostat for the treatment of benign prostatic hyperplasia (BPH). METHODS: An open, multicentral clinical trial was conducted in 100 patients with BPH. Patients received a 12-week oral administration of Eviprostat 2 tablets per-time, 3 times a day. The main indexes of efficacy include international prostatic symptom score (IPSS), maximum urinary flow rate (Qmax), residual urine (Ru) and prostatic volume (V). The additional indexes are quality of life score (QOL) and average urinary flow rate (Qave). RESULTS: After a 12-week therapy, IPSS, QOL score, Qmax and Qave were significantly improved. IPSS was averagely decreased by 5.67 (P < 0.001); QOL score was averagely decreased by 1.44 (P < 0.001); Qmax was averagely increased by 1.70 ml/s (P <0.001); Qave was averagely increased by 1.15 ml/s (P < 0.001); Ru was averagely decreased by 5.07 ml (P = 0.046) , PSA level was averagely decreased by 0.129 microg/L (P < 0.017). The clinical adverse event rate was 1%. CONCLUSION: Eviprostat is a kind of safe, effective and preferable drug for treating BPH. It can improve the subjective symptoms and objective measures of the patients. SN - 1009-3591 UR - https://www.unboundmedicine.com/medline/citation/16209208/[Clinical_study_of_Eviprostat_for_the_treatment_of_benign_prostatic_hyperplasia]_ L2 - http://www.diseaseinfosearch.org/result/9668 DB - PRIME DP - Unbound Medicine ER -